Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy
Salloum, Ramzi G
Elchynski, Amanda L
Smith, D Max
Blake, Kathryn V
Limdi, Nita A
Aquilante, Christina L
Beitelshees, Amber L
Duong, Benjamin Q
Empey, Philip E
Formea, Christine M
Hicks, J Kevin
Pasternak, Amy L
Ramsey, Laura B
Swain, Sandra M
Ward, Kristen M
Skaar, Todd C
Van Driest, Sara L
Cavallari, Larisa H
Bishop, Jeffrey R
JournalClinical and Translational Science
MetadataShow full item record
AbstractThere is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented or were in the process of implementing PGx testing for antidepressants. Survey 1 collected data on the process and logistics of testing. Survey 2 asked sites to rank the importance of Consolidated Framework for Implementation Research (CFIR) constructs using best-worst scaling choice experiments. Of the 17 sites, 13 had implemented testing and four were in the planning stage. Thirteen offered testing in the outpatient setting, and nine in both outpatient/inpatient settings. PGx tests were mainly ordered by psychiatry (92%) and primary care (69%) providers. CYP2C19 and CYP2D6 were the most commonly tested genes. The justification for antidepressants selected for PGx guidance was based on Clinical Pharmacogenetics Implementation Consortium guidelines (94%) and US Food and Drug Administration (FDA; 75.6%) guidance. Both institutional (53%) and commercial laboratories (53%) were used for testing. Sites varied on the methods for returning results to providers and patients. Sites were consistent in ranking CFIR constructs and identified patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and the identification of champions as most important for implementation. Sites deployed similar implementation strategies and measured similar outcomes. The process of implementing PGx testing to guide antidepressant therapy varied across sites, but key drivers for successful implementation were similar and may help guide other institutions interested in providing PGx-guided pharmacotherapy for antidepressant management. © 2021 The Authors.
Rights/Terms© 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16782
- Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing.
- Authors: Vest BM, Wray LO, Brady LA, Thase ME, Beehler GP, Chapman SR, Hull LE, Oslin DW
- Issue date: 2020 Oct 28
- Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
- Authors: Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH, IGNITE Network Pharmacogenetics Working Group.
- Issue date: 2021 Jul 19
- Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.
- Authors: Fabbri C, Zohar J, Serretti A
- Issue date: 2018 Aug 30
- Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes.
- Authors: Hagedorn HJ, Wisdom JP, Gerould H, Pinsker E, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Harris AHS
- Issue date: 2019 Jul 10
- Suicidal Ideation
- Authors: Harmer B, Lee S, Duong TvH, Saadabadi A
- Issue date: 2021 Jan